Stockscreener 앱 받기
9.83
4.46%
0.42
시장 영업 전:
10.03
0.20
+2.03%
전일 마감가:
$9.41
열려 있는:
$9.36
하루 거래량:
510.85K
Relative Volume:
0.99
시가총액:
$514.63M
수익:
$9.68M
순이익/손실:
$-244.09M
주가수익비율:
-2.1678
EPS:
-4.5346
순현금흐름:
$-168.85M
1주 성능:
+0.72%
1개월 성능:
-8.30%
6개월 성능:
-6.20%
1년 성능:
+50.08%
1일 변동 폭
$9.36
$10.00
1주일 범위
$9.02
$10.09
52주 변동 폭
$4.32
$11.80
Prothena Corp Plc Stock (PRTA) Company Profile
명칭
Prothena Corp Plc
전화
011-353-1-236-2500
주소
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRTA
Prothena Corp Plc
|
9.83 | 492.64M | 9.68M | -244.09M | -168.85M | -4.5346 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prothena Corp Plc Stock (PRTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-05-27 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-05-27 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-27 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-01-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-04-24 | 개시 | SVB Securities | Outperform |
| 2023-01-27 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-11-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-06-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-08 | 재확인 | Oppenheimer | Outperform |
| 2021-05-26 | 개시 | Citigroup | Buy |
| 2021-02-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-12-07 | 개시 | H.C. Wainwright | Buy |
| 2020-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-05-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-04-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-04-05 | 재확인 | Barclays | Overweight |
| 2017-11-20 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2017-09-29 | 재확인 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Jefferies | Buy |
| 2017-04-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-04-12 | 개시 | Piper Jaffray | Overweight |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-12-21 | 개시 | SunTrust | Buy |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-08-04 | 재확인 | Barclays | Overweight |
| 2016-05-13 | 개시 | Barclays | Overweight |
| 2016-02-19 | 재확인 | Wedbush | Outperform |
| 2016-01-21 | 개시 | Credit Suisse | Outperform |
모두보기
Prothena Corp Plc 주식(PRTA)의 최신 뉴스
Prothena (NASDAQ: PRTA) investors approve board, KPMG and executive pay - Stock Titan
Rubric Capital and David Rosen disclose 9.29% stake in Prothena (PRTA) - Stock Titan
Prothena Corp plc stock (IE00B91XRN20): Biotech investor focus amid pipeline updates - AD HOC NEWS
Number of shareholders of Prothena Corp. Plc – DUS:0PT - TradingView
PRTA Stock Price, Quote & Chart | PROTHENA CORP PLC (NASDAQ:PRTA) - ChartMill
William Scully reports 10.27% stake in PROTHENA (NASDAQ: PRTA) - Stock Titan
Prothena Corp. Down Over 9%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
Earnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Prothena (PRTA) Heavy US$244 Million Annual Loss Tests Bullish Profitability Narratives - Sahm
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment - Yahoo Finance
Prothena (PRTA) Highlights Progress in Parkinson's Research and Collaborations - GuruFocus
Citizens raises Prothena stock price target on milestone payment By Investing.com - Investing.com UK
Prothena (PRTA) Revises 2026 Cash Outlook and Operating Expenses - GuruFocus
Prothena (NASDAQ:PRTA) Smashes Q1 Estimates on $50 Million Milestone Payment, Shares Steady - ChartMill
Prothena: Q1 Earnings Snapshot - marketscreener.com
Milestone revenue lifts Prothena (NASDAQ: PRTA) cash and pipeline - Stock Titan
Prothena (NASDAQ: PRTA) posts $32.7M Q1 profit and lifts 2026 cash outlook - Stock Titan
A $50M Novo milestone reshaped Prothena’s 2026 cash outlook - Stock Titan
Prothena to Report First Quarter 2026 Financial Results on May 7 - ChartMill
3 Growth Companies Insiders Are Eager To Hold - Sahm
Prothena (NASDAQ:PRTA) Shares Up 5.9%Time to Buy? - MarketBeat
FDA Fast Track granted to Phase 3 drug for ATTR-CM - Stock Titan
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy - The Joplin Globe
Prothena authorizes up to $100 million share repurchase plan - MSN
PRTA SEC FilingsProthena 10-K, 10-Q, 8-K Forms - Stock Titan
Price vs Value Analysis | Prothena Corporation posts 29.8% EPS beat with narrower loss - Cổng thông tin điện tử tỉnh Lào Cai
PRTA (Prothena Corporation plc Ordinary Shares) rises 3.61 percent after Q4 2025 EPS outpaces analyst consensus estimates.AI Powered Stock Picks - Xã Châu Thành
Liquidity Mapping Around (PRTA) Price Events - Stock Traders Daily
Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Prothena (NASDAQ:PRTA) Share Price Passes Above 200-Day Moving AverageTime to Sell? - MarketBeat
Prothena Corp plc stock (IE00B91XRN20): Why does its biotech pipeline matter more now for investors? - AD HOC NEWS
Prothena FY25 Earnings Review: Partnered Programs Advance Toward Milestones as Wholly-Owned Assets Pivot - AlphaStreet
Prothena Announces Leadership Team Updates - National Today
Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN
Why (PRTA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Prothena Corp PLC (PRTA) Stock Earnings Transcripts - GuruFocus
Prothena (NASDAQ: PRTA) awards 100,000 stock options to Chief Strategy Officer - Stock Titan
Prothena (PRTA) Chief Strategy Officer reports 66,942 shares and option grants - Stock Titan
Prothena (PRTA) Strengthens Leadership Team with Key Promotions - GuruFocus
Prothena promotes Kingston, Isaacs to leadership roles - Investing.com
Prothena Corporation Announces Leadership Team Updates to Support Pipeline Development - geneonline.com
Prothena promotes Kingston, Isaacs to leadership roles By Investing.com - Investing.com India
Insider Sell: Will Prothena Corporation plc outperform tech stocksQuarterly Investment Review & Verified Swing Trading Watchlist - baoquankhu1.vn
PRTA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Published on: 2026-04-07 04:52:36 - baoquankhu1.vn
Is Prothena (PRTA) Stock Trending Down | Price at $10.05, Up 1.93%Real-time Trade Ideas - newser.com
Analyst Calls: How do insiders feel about Prothena Corporation plc2026 Chart Watch & Daily Entry Point Alerts - baoquankhu1.vn
Gap Down: Can Prothena Corporation plc be recession proofWeekly Trend Report & AI Driven Price Predictions - baoquankhu1.vn
Prothena Corp plc Stock: Clinical Milestones and Strategic Focus in Biotechnology Drive Investor Int - AD HOC NEWS
PRTA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
PRTA Technical Analysis & Stock Price Forecast - Intellectia AI
Prothena Corp Plc (PRTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):